Cancer

Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology

Publication Date	October 2006
Publisher	Bioseeker
Product Type	Report
Pages	124
ISBN Number	not applicable
Product Code	BSK00131

Price

£1,745.00
approximately: $2,642 | €1,948

pdf

print

Order above formats by FAX

With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents.

Scope of this report

In-depth competitive landscape assessment of the anti-angiogenesis market in oncology
Thorough review of utilized targets in anti-angiogenic and vascular target drug development
Thorough review of approved drugs
Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

Companies with the ten highest numbers of clinical trials make up more than 40% of all research and development done in anti-angiogenesis and vascular targeting in onoclogy, but they just constitute 10% of the competitors in the field.
More than 100 anti-angiogenic drugs have been described with one or more targets. These 75 drug targets are a mixture of weaker and stronger targets in angiogenesis.
The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations, BioSeeker identifies that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.

Key reasons to read this report

Understand the clinical and strategic challenges to the commercialization of anti-angiogenic and vascular targeting drugs
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.
Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Some of the almost 100 drugs included in this analysis

2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK, sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474, volociximab etc.

Some of the more than 100 companies included in this analysis

Adherex, Aeterna Zentaris, Amgen, AstraZeneca, Bayer, Celgene, Chugai, Eli Lilly, EntreMed, Eisai, Exelixis, Genaera, Genentech, Hoffmann-La Roche, Merck KGaA, Novartis, OXiGENE, PDL BioPharma, PharmaMar, Wilex etc.

1. Executive Summary
2. Cancer Highlights
3. Methodology
4. Table of Contents
- 4.1 List of Boxes
- 4.2 List of Figures
- 4.3 List of Tables
5. Introduction
- 5.1 Neoplastic Angiogenesis & Tumor Vasculature
  - 5.1.1 Tumor Vasculature
  - 5.1.2 The Current Model of Sprouting Angiogenesis
- 5.2 Main Angiogenic Factors
  - 5.2.1 Vascular Endothelial Growth Factor
  - 5.2.2 The Angiopoietins and Platelet Derived Growth Factor
  - 5.2.3 Integrins in Angiogenesis
  - 5.2.4 Inhibitors of Angiogenesis
- 5.3 Vascular Targeting Agents
- 5.4 Vascular Disruptive Agents
6. Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology
- 6.1 Countries & Players: Who are In the Lead?
  - 6.1.1 Top 10 Players Dominate The Developmental Pipeline
- 6.2 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
  - 6.2.1 Review of Deals and Alliances Initiated in 2005
  - 6.2.2 Review of Deals and Alliances Initiated in 2004
  - 6.2.3 Review of Deals and Alliances Initiated in 2003
7. Approved Anti-Angiogenic Cancer Drugs: Performance
8. Target Analysis in Anti-Angiogenesis and Vascular Targeting
- 8.1 Targets of Late Stage Anti-Angiogenic Drugs in Development
  - 8.1.1 Drugs with Epidermal Growth Factor Receptor as a Target
  - 8.1.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
  - 8.1.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
  - 8.1.4 Drugs with Kinase Insert Domain Receptor as a Target
  - 8.1.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
  - 8.1.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
  - 8.1.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
  - 8.1.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
  - 8.1.9 Drugs with Protein Kinase C, beta 1 as a Target
  - 8.1.10 Drugs with Ret Proto-Oncogene as a Target
  - 8.1.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
  - 8.1.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
  - 8.1.13 Drugs with Vascular Endothelial Growth Factor as a Target
- 8.2 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer Indications
  - 8.2.1 Targets in Breast Cancer
  - 8.2.2 Targets in Colorectal Cancer
  - 8.2.3 Targets in Lung Cancer
  - 8.2.4 Targets in Prostate Cancer
  - 8.2.5 Targets in Renal Cancer
9. Anti-angiongenesis and Vascular Targeting Drugs in Development: By Major Indications
- 9.1 General Drug Developmental Overview
- 9.2 Progress Analysis - Breast Cancer
  - 9.2.1 Phase I Clinical Development
  - 9.2.2 Phase II Clinical Development
  - 9.2.3 Phase III Clinical Development
- 9.3 Progress Analysis - Colorectal Cancer
  - 9.3.1 Phase I Clinical Development
  - 9.3.2 Phase II Clinical Development
  - 9.3.3 Phase III Clinical Development
- 9.4 Progress Analysis - Lung Cancer
  - 9.4.1 Phase I Clinical Development
  - 9.4.2 Phase II Clinical Development
  - 9.4.3 Phase III Clinical Development
- 9.5 Progress Analysis - Prostate Cancer
  - 9.5.1 Phase I Clinical Development
  - 9.5.2 Phase II Clinical Development
  - 9.5.3 Phase III Clinical Development
- 9.6 Progress Analysis - Renal Cancer
  - 9.6.1 Phase I Clinical Development
  - 9.6.2 Phase II Clinical Development
  - 9.6.3 Phase III Clinical Development
10. Disclaimer
- 10.1 Liability
- 10.2 Completeness
11. Appendix I: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology
12. Drug Index
13. Company Index

List of Boxes
- Box 1: Nexavar's Clinical Data That Lead To Its EMEA Approval Myeloma
- Box 2: Thalomid Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
- Box 3: Strong Clinical Data Suggests Approval to Market Avastin For The Treatment of Both Breast Cancer and NSCLC
- Box 4: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic Cancer
- Box 5: Business & Market - Cilengitide
- Box 6: Business & Market - Exherin
- Box 7: Business & Market - WX-UK1
- Box 8: Business & Market - Combretastatin A-4 phosphate
- Box 9: Business & Market - GCS-100LE
- Box 10: Business & Market - PTK/ZK
- Box 11: Business & Market - AS-1404
- Box 12: Business & Market - Phosphomannopentaose sulfate
- Box 13: Business & Market - Squalamine
- Box 14: Business & Market - talactoferrin alfa
- Box 15: Business & Market - ZD-6474
- Box 16: Business & Market - AP-23573
- Box 17: Business & Market - Volociximab
- Box 18: Business & Market - XL-999
List of Figures
- Figure 1: Establishment of Blood Supply to Tumors
- Figure 2: Sprouting Angiogenesis
- Figure 3: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting Research
- Figure 4: Top 10 Companies' Clinical Trial Progress in Anti-Angiogenesis and Vascular Targeting
- Figure 5: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting 2001-2005
- Figure 6: Annual Sales of Avastin on US and Non US Markets
- Figure 7: Trial Distribution of the Entire Anti-Angiogenic and Vascular Target Agent Field in Oncology
- Figure 8: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Breast Cancer
- Figure 9: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Colorectal
- Figure 10: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Lung Cancer
- Figure 11: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Prostate Cancer
- Figure 12: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Renal Cancer
List of Tables
- Table 1: Top 10's Anti-angiogenic and Vascular Targeting Pipeline Drugs
- Table 2: Deals & Alliances in 2005
- Table 3: Deals & Alliances in 2004
- Table 4: Deals & Alliances in 2003
- Table 5: Companies with Cancer Anti-angiogenic Drugs on the Market
- Table 6: 2006 Q2 Sales Revlimid and Thalomid
- Table 7: 2006 Q2 Sales of Avastin
- Table 8: List of 75 Known Targets in Ant-angiogenis and Vascular Targeting in Drug Development
- Table 9: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
- Table 10: Drugs with Epidermal Growth Factor Receptor as a Target
- Table 11: Drugs with FMS-related Tyrosine Kinase 1 as a Target
- Table 12: Drugs with FMS-related Tyrosine Kinase 4 as a Target
- Table 13: Drugs with Kinase Insert Domain Receptor as a Target
- Table 14: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
- Table 15: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
- Table 16: Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
- Table 17: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
- Table 18: Drugs with Protein Kinase C, beta 1 as a Target
- Table 19: Drugs with Ret Proto-Oncogene as a Target
- Table 20: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
- Table 21: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
- Table 22: Drugs with Vascular Endothelial Growth Factor as a Target
- Table 23: Breast Cancer Targets in Anti-Angiogenic Drug Development
- Table 24: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
- Table 25: Lung Cancer Targets in Anti-Angiogenic Drug Development
- Table 26: Prostate Cancer Targets in Anti-Angiogenic Drug Development
- Table 27: Renal Cancer Targets in Anti-Angiogenic Drug Development
- Table 28: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular Targeting Cancer Drugs